INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is the fifth most common type of malignancy among males and the fourth most common type among females in China, accounting for 215,700 and 160,600 cases in 2015, respectively \[[@R1]\]. The incidence of CRC is rapidly increasing in developing countries including China \[[@R1], [@R2]\]; however, the etiology of CRC remians unknown. Risk factors, such as family history of CRC, advanced age, inflammatory bowel diseases, benign adenomatous polyps, being physically inactive, drinking, smoking, high intake of dietary fat and low intake of vegetables and fruits, may play important roles in the development of CRC \[[@R3]--[@R9]\]. Accumulating evidence suggested that besides individual lifestyle and environmental factors, some genetic factors may be relevant to the etiology of CRC.

The gene of peroxisome proliferator-activated receptor gamma (*PPARG*), a ligand-activated transcription factor, is located in 3p25. PPARG shares conservative domain with other steroid receptors (e.g., the vitamin D, estrogen, progesterone, retinoid and thyroid receptors), which recognize to peroxisome proliferator-activated receptor (PPAR) response elements in the region of promoter, and then bind to them. Subsequently, these steroid receptors regulate the transcription of some target genes. It is well known that PPARG may be involved in controlling adipocytes differentiation, regulating energy homeostasis, influence of cellular cholesterol homoeostasis, and the development of type 2 diabetes mellitus (T2DM) and obesity \[[@R10]--[@R12]\].

Many investigations evidenced the potential roles of *PPARG* gene in determining CRC susceptibility. Understanding the variants in this gene correlated with CRC susceptibility may be helpful for CRC prevention and diagnosis. Recently, some case-control studies focused on the relationship of *PPARG* polymorphisms with the risk of CRC. A common single nucleotide polymorphism in *PPARG* gene \[rs1801282 C\>G (Pro12Ala)\] have been established, which were associated with receptor activity, insulin sensitivity, body mass index (BMI), and risk of T2DM \[[@R13], [@R14]\]. Many studies focused on the association of *PPARG* rs1801282 C\>G polymorphism with risk of CRC. Several meta-analyses demonstrated that *PPARG* rs1801282 C\>G polymorphism was associated with the decreased risk of CRC in Caucasians \[[@R15], [@R16]\]. However, there were only three case-control studies with relatively small sample sizes focused on the relationship between *PPARG* rs1801282 C\>G polymorphism and CRC in Asians \[[@R17]--[@R19]\]. The evidence may be limited.

The biological significance of PPARG indicates that functional polymorphisms in *PPARG* gene may influence the susceptibility of CRC. Thus, the attempt of the present study was to assess the relationship of rs1801282 variations in *PPARG* with CRC risk. The results of our case-control study might be limited by sample size. With the aim to overcome this limitation, a comprehensive pooled-analysis was subseqently carried out to determine the association of *PPARG* rs1801282 C\>G polymorphism with CRC risk.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

Table [1](#T1){ref-type="table"} summarized the distribution of demographic variables and risk factors in CRC cases and controls. We found there was no significant difference in the distributions of age (cases: 60.21 ± 12.48, vs. controls: 60.82 ± 8.82; *P* = 0.272), sex (*P* = 0.213), smoking (*P* = 0.505) and alcohol consumption (*P* = 0.058) between cases and controls. CRC patients have relatively lower body mass index (BMI) than that of the control subjects (*P* \< 0.001). When it comes to TMN stages, according to AJCC criteria from 2010, 196 and 191 CRC patients were classified as stage I/II and III/IV, respectively. The primary information of *PPARG* rs1801282 C\>G polymorphism was listed in Table [2](#T2){ref-type="table"}. The genotype distributions of *PPARG* rs1801282 C\>G polymorphism in controls were in accordance with HWE (*P* = 0.544).

###### Distribution of selected demographic variables and risk factors in colorectal cancer cases and controls

  Variable                       Cases (*n* = 387)   Controls (*n* = 1,536)   *P*^a^                   
  ------------------------------ ------------------- ------------------------ ---------------- ------- ----------
  Age (years)                    60.21 (± 12.48)     60.82 (± 8.85)           0.272                    
  Age (years)                                                                                          0.502
   \< 61                         186                 48.06                    709              46.16   
   ≥ 61                          201                 51.94                    827              53.84   
  Sex                                                                                                  0.213
   Male                          236                 60.98                    989              64.39   
   Female                        151                 39.02                    547              35.61   
  Smoking status                                                                                       0.505
   Never                         270                 69.77                    1098             71.48   
   Ever                          117                 30.23                    438              28.52   
  Alcohol use                                                                                          0.058
   Never                         335                 78.55                    1381             89.91   
   Ever                          52                  21.45                    155              10.09   
  BMI (kg/m^2^)                  22.70 (± 3.16)                               24.05 (± 3.15)           \< 0.001
  BMI (kg/m^2^)                                                                                        \< 0.001
   \< 24                         263                 67.96                    775              50.46   
   ≥ 24                          124                 32.04                    761              49.54   
  Site of tumor                                                                                        
   Colon cancer                  169                 43.67                                             
   Rectum cancer                 218                 56.33                                             
  Degree of differentiation^b^                                                                         
   Low                           56                  16.28                                             
   Medium                        261                 75.87                                             
   High                          27                  7.85                                              
  Lymph node status                                                                                    
   Positive                      177                 45.74                                             
   Negative                      210                 54.26                                             
  TMN stage                                                                                            
   I + II                        196                 50.65                                             
   III + IV                      191                 49.35                                             

^a^Two-sided χ^2^ test and student *t* test; BMI, body mass index; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ^b^six subjects have missing data.

###### Primary information of the *PPARG* rs1801282 C\>G polymorphism

  Genotyped SNPs                              *PPARG* rs1801282 C\>G
  ------------------------------------------- ------------------------
  Chromosome                                  3
  Chr Pos (NCBI Build 37)                     12393125
  Function                                    missense
  MAF for Chinese in database                 0.07
  MAF in our controls (*n* = 1,536)           0.05
  *P* value for HWE^f^ test in our controls   0.544
  Genotyping method                           SNPscan
  \% Genotyping value                         99.64

MAF: minor allele frequency;

HWE: Hardy--Weinberg equilibrium.

Association of *PPARG* rs1801282 C\>G polymorphism with CRC risk {#s2_2}
----------------------------------------------------------------

Table [3](#T3){ref-type="table"} summarizes the genotype distributions of *PPARG* rs1801282 C\>G polymorphism in CRC cases and controls. The genotype frequencies of *PPARG* rs1801282 C\>G were 93.21% (CC), 6.53% (CG) and 0.26% (GG) in CRC patients, which were not significantly different from those in non-cancer controls (90.28% CC, 9.39% CG and 0.33% GG). When compared with the frequency of *PPARG* rs1801282 CC genotype, individuals carrying the CG genotype had a tendency of decreased risk to CRC risk (crude OR = 0.67, 95% CI = 0.43--1.04 for CG vs. CC, *P* = 0.072). When compared with the frequency of *PPARG* rs1801282 CC genotype, individuals carrying the GG genotype also had this tendency to CRC risk (crude OR = 0.68, 95% CI = 0.44--1.04 for GG vs. CC, *P* = 0.077). Adjustments for age, sex, smoking, drinking and BMI, the observed tendency was not essentially changed (CG vs. CC: adjusted OR, 0.67, 95% CI = 0.43--1.04 for CG vs. CC, *P* = 0.073; GG vs. CC: adjusted OR, 0.68; 95% CI, 0.44--1.05; *P* = 0.078; Table [4](#T4){ref-type="table"}). Results of other genetic comparisons are listed in Table [4](#T4){ref-type="table"}.

###### The frequencies of *PPARG* rs1801282 C\>G polymorphism in colorectal cancer patients and controls

  Genotype   CRC cases (*n* = 387)   Colon cancer (*n* = 169)   Rectum cancer (*n* = 218)   Controls (*n* = 1,536)                          
  ---------- ----------------------- -------------------------- --------------------------- ------------------------ ----- -------- ------- -------
  CC         357                     93.21                      157                         94.01                    200   92.59    1,384   90.28
  GC         25                      6.53                       9                           5.39                     16    7.41     144     9.39
  GG         1                       0.26                       1                           0.60                     0     0        5       0.33
  GC+GG      26                      6.79                       10                          5.99                     16    7.41     149     9.72
  CC+GC      382                     99.74                      166                         99.40                    216   100.00   1,528   99.67
  GG         1                       0.26                       1                           0.60                     0     0        5       0.33
  G allele   27                      3.52                       11                          3.29                     16    3.70     154     5.02

###### Overall and stratified analyses of *PPARG* rs1801282 C\>G polymorphism with colorectal cancer by region

  Genotype           Overall colorectal cancer cases (*n* = 387) vs. controls (1,536)   Colon cancer (*n* = 169) vs. controls (1,536)   Rectum cancer (*n* = 218) vs. controls (1,536)                                                                                                                     
  ------------------ ------------------------------------------------------------------ ----------------------------------------------- ------------------------------------------------ ------- -------------------- ------- -------------------- ------- ------------------- ------- ------------------- -------
  Additive model     0.67 (0.43--1.04)                                                  0.072                                           0.67 (0.43--1.04)                                0.073   0.55 (0.27--1.09)    0.086   0.54 (0.27--1.08)    0.083   0.76 (0.45--1.31)   0.324   0.77 (0.45--1.32)   0.335
  Homozygote model   0.77 (0.09--6.60)                                                  0.810                                           0.77 (0.09--6.82)                                0.814   1.75 (0.20--15.03)   0.612   1.80 (0.21--15.73)   0.596   --                  --      --                  --
  Dominant model     0.68 (0.44--1.04)                                                  0.077                                           0.68 (0.44--1.05)                                0.078   0.59 (0.31--1.15)    0.120   0.59 (0.30--1.14)    0.117   0.76 (0.45--1.31)   0.324   0.77 (0.45--1.32)   0.335
  Recessive model    0.80 (0.09--6.87)                                                  0.839                                           0.80 (0.09--7.07)                                0.838   1.84 (0.21--12.85)   0.579   1.89 (0.22--16.57)   0.566   --                  --      --                  --

^a^Adjusted for age, sex, smoking status, alcohol use and BMI status in a logistic regression.

Association of *PPARG* rs1801282 C\>G polymorphism with CRC risk in a stratification group by site of tumor {#s2_3}
-----------------------------------------------------------------------------------------------------------

To assess the effect of *PPARG* rs1801282 C\>G polymorphism in different tumor site, a stratified analysis was conducted. The stratified analysis revealed *PPARG* rs1801282 C\>G polymorphism also had a tendency of decreased risk to colon cancer (CG *vs.* CC: adjusted OR = 0.54, 95% CI = 0.27--1.08, *P* = 0.083; Table [4](#T4){ref-type="table"}).

Meta-analysis of *PPARG* rs1801282 C\>G polymorphism and CRC risk {#s2_4}
-----------------------------------------------------------------

Next, a comprehensive meta-analysis was carried out to determine the relationship between *PPARG* polymorphisms and CRC risk. In total, 219 abstracts were retrieved from Pubmed and EMBASE databases. The detailed selecting process is summarized in Figure [1](#F1){ref-type="fig"}. There were several subgroups in our present study and some publications \[[@R17], [@R19]--[@R22]\], we treated them separately. The detailed characteristics and *PPARG* rs1801282 genotypes of included studies are listed in Table [5](#T5){ref-type="table"}. Finally, our present study and previously published studies involving 12,761 cases and 21,113 controls were recruited in this pooled-analysis.

![Flow chart of study selection procedure](oncotarget-08-100558-g001){#F1}

###### Characteristics of the eligible studies included in the meta-analysis for *PPARG* rs1801282 C\>G polymorphism

  Study                   Year   Country       Ethnicity    Type                Case/Control   Case    Control   HWE                          
  ----------------------- ------ ------------- ------------ ------------------- -------------- ------- --------- ----- ------- --------- ---- -----
  Our study               2016   China         Asians       Colon cancer        169/1,536      157     9         1     1,384   144       5    Yes
  Our study               2016   China         Asians       Rectum cancer       218/1,536      200     16        0     1,384   144       5    Yes
  Crous-Bou et al.        2012   Israel        Caucasians   Colorectal cancer   1,780/1,864    710     102       0     1,307   163       9    Yes
  Sainz et al.            2012   German        Caucasians   Colorectal cancer   1,801/1,783    1,354   415       32    1,334   427       22   Yes
  Abuli et al.            2011   Spain         Caucasians   Colorectal cancer   515/502        426     87        2     419     80        3    Yes
  Tsilidis et al.         2009   USA           Caucasians   Colorectal cancer   208/381        165     37        1     295     68        6    Yes
  Kury et al.             2008   France        Caucasians   Colorectal cancer   1,023/1,121    822     194       7     896     212       13   Yes
  Vogel et al.            2007   Denmark       Caucasians   Colorectal cancer   355/753        252     96        7     550     190       13   Yes
  Kuriki et al.           2006   Japan         Asians       Colorectal cancer   128/238        120     7         0     221     17        0    Yes
  Theodoropoulos et al.   2006   Greece        Caucasians   Colorectal cancer   222/200        164     48        10    118     70        12   Yes
  Slattery et al.         2006   USA           Caucasians   Colorectal cancer   2,371/2,972    1,840   496       35    2,283   645       44   Yes
  Siezen et al.           2006   Netherlands   Caucasians   Colorectal cancer   204/399        160     40        1     325     70        2    Yes
  Siezen et al.           2006   Netherlands   Caucasians   Colorectal cancer   487/750        387     92        8     596     146       8    Yes
  Gunter et al.           2006   USA           Caucasians   Colorectal cancer   244/231        151     54        4     141     52        3    Yes
  Koh et al.              2006   Singapore     Asians       Colon cancer        206/1,164      195     11^\*^    \-    1,057   89^\*^    \-   Yes
  Koh et al.              2006   Singapore     Asians       Rectum cancer       156/1,164      150     6^\*^     \-    1,057   89^\*^    \-   Yes
  McGreavey et al.        2005   UK            Caucasians   Colorectal cancer   478/733        366     80        9     403     100       10   Yes
  Jiang et al.            2005   India         Asians       Colon cancer        59/291         46      13        0     230     57        4    Yes
  Jiang et al.            2005   India         Asians       Recum cancer        242/291        194     44        4     230     57        4    Yes
  Gong et al.             2005   USA           Caucasians   Colorectal cancer   163/212        129     30        4     153     52        7    Yes
  Murtaugh et al.         2005   USA           Caucasians   Colon cancer        1,577/1,971    1,234   343^\*^   \-    1,493   478^\*^   \-   Yes
  Murtaugh et al.         2005   USA           Caucasians   Recum cancer        794/1,001      606     188^\*^   \-    790     211^\*^   \-   Yes
  Landi et al.            2003   Spain         Caucasians   Recum cancer        139/326        111     15        3     243     61        5    Yes
  Landi et al.            2003   Spain         Caucasians   Colon cancer        238/326        200     31        0     243     61        5    Yes
  Smith et al.            2001   UK            Caucasians   Recum cancer        37/49          37      3         0     49      11        2    Yes

^\*^GG+CG;

HWE: Hardy-Weinberg equilibrium.

Overall, a significant association was identified between *PPARG* rs1801282 C\>G polymorphism and decreased risk of CRC (G vs. C: OR = 0.94, 95% CI = 0.89--1.00, *P* = 0.040; GG+CG vs. CC: OR = 0.92, 95% CI = 0.84--0.99, *P* = 0.032, Figure [2](#F2){ref-type="fig"}). First, a further subgroup analysis was conducted by the ethnicity. Evidence of significant association between *PPARG* rs1801282 C\>G polymorphism and decreased risk of CRC were also found among Asians (GG+CG vs. CC: OR = 0.76, 95% CI = 0.60--0.95, *P* = 0.018, [Supplementary Table 1](#SD2){ref-type="supplementary-material"}), but not Caucasians. Next, a further subgroup analysis was conducted by CRC region. *PPARG* rs1801282 C\>G polymorphism was associated with decreased risk of colon cancer (G vs. C: OR = 0.66, 95% CI = 0.48--0.90, *P* = 0.009, GG+CG vs. CC: OR = 0.82, 95% CI = 0.71--0.94, *P* = 0.004, CG vs. CC + GG: OR = 0.70, 95% CI = 0.50--0.98, *P* = 0.035 and CG vs. CC: OR = 0.69, 95% CI = 0.49--0.96, *P* = 0.029; [Supplementary Table 1](#SD2){ref-type="supplementary-material"}), and rectum cancer (G vs. C: OR = 0.77, 95% CI = 0.59--0.99, *P* = 0.042, CG vs. CC + GG: OR = 0.73, 95% CI = 0.55--0.97, *P* = 0.032 and CG vs. CC: OR = 0.73, 95% CI = 0.55--0.97, *P* = 0.032; [Supplementary Table 1](#SD2){ref-type="supplementary-material"}), but not mixed type of CRC.

![Forest plot of association between *PPARG* rs1801282 C\>G polymorphism and CRC risk in random model (GG+CG vs. CC)](oncotarget-08-100558-g002){#F2}

Both Begg's test and Egger's test were used to assess the potential publication bias in our study. It suggested that there was significant publication bias in some genetic models (G vs. C: Begg's test *P* = 0.005, Egger's test *P* = 0.009; GG vs. CC: Begg's test *P* = 0.127, Egger's test *P* = 0.026; GG+CG vs. CC: Begg's test *P* = 0.005, Egger's test *P* = 0.011; GG vs. CC+CG: Begg's test *P* = 0.112, Egger's test *P* = 0.024; CG vs. CC+GG: Begg's test *P* = 0.010, Egger's test *P* = 0.031 and CG vs. CC: Begg's test *P* = 0.007, Egger's test *P* = 0.026; Figure [3](#F3){ref-type="fig"}). Thus, adjusted ORs and CIs of nonparametric "trim-and-fill" method were harnessed to assess the stability of our findings. The adjusted ORs and CIs were: G vs. C: adjusted pooled OR = 0.94, 95% CI: 0.89--1.00, *P* = 0.054; GG vs. CC: adjusted pooled OR = 0.97, 95% CI: 0.76--1.23, *P* = 0.789; GG+CG vs. CC: adjusted pooled OR = 0.92, 95% CI: 0.85--0.99, *P* = 0.032; GG vs. CG+CC: adjusted pooled OR = 1.00, 95% CI: 0.79--1.26, *P* = 0.979; CG vs. CC+GG: adjusted pooled OR = 0.94, 95% CI: 0.88--1.01, *P* = 0.069 and CG vs. CC: adjusted pooled OR = 0.94, 95% CI: 0.88--1.00, *P* = 0.066 (Figure [4](#F4){ref-type="fig"}). These results suggested that our findings were stable.

![Begger's funnel plot of the meta-analysis of between *PPARG* rs1801282 C\>G polymorphism and CRC risk in random model (GG+CG vs. CC)](oncotarget-08-100558-g003){#F3}

![Filled funnel plot of the meta-analysis of between *PPARG* rs1801282 C\>G polymorphism and CRC risk in random model (GG+CG vs. CC)](oncotarget-08-100558-g004){#F4}

Using the exclusion method in turn, one-way sensitivity analysis was performed to determine whether an included study could affect the final decision. The results showed that our findings were stable and reliable (Figure [5](#F5){ref-type="fig"}).

![Sensitivity analysis on association between *PPARG* rs1801282 C\>G polymorphism and CRC risk in random model (GG+CG vs. CC)](oncotarget-08-100558-g005){#F5}

For *PPARG* rs1801282 C\>G polymorphism, the power value (α = 0.05) was 0.529 in G vs. C genetic model and 0.810 in GG/CG vs. CC genetic model among overall CRC cancer group, 0.717 in G vs. C genetic model, 0.791 in GG/CG vs. CC genetic model, 0.528 in CG vs. GG/CC genetic model and 0.562 in CG vs. CC genetic among colon cancer group, and 0.474 in G vs. C genetic model, 0.554 in CG vs. GG/CC genetic model and 0.552 in CG vs. CC genetic among rectum cancer group. In addition, for *PPARG* rs1801282 C\>G, the power value was 0.660 in GG/CG vs. CC genetic model among Asians.

DISCUSSION {#s3}
==========

PPARG is a nuclear hormone receptor, and mainly exists in colorectum, adipose tissue, and immune system \[[@R23]\]. PPARG plays a very important role in the inflammatory response, adipose cell differentiation, modulation of metabolism, and cellular apoptosis \[[@R24]--[@R27]\]. PPARG regulates and/or interacts with multifarious signaling pathways, including those associated with p21, p53, NF-kappa-β, STAT, BCL2, cyclooxygenase-2 (COX-2) and cyclin D1 \[[@R24]--[@R26], [@R28], [@R29]\]. PPARG is highly expressed in tumour cells, and treatment with PPARG ligands can induce cell apoptosis and differentiation \[[@R30]--[@R32]\]. *PPARG* mutation may increase CRC risk \[[@R22]\]. The possible association of *PPARG* rs1801282 C\>G polymorphism with CRC risk has been extensively studied; however, findings of those investigations were conflicting, especially in Asians. To obtain a more precise assessment of these potential associations, we conducted a case-control study. Then, given the accumulating evidences and to shed some light on this issue, we performed a pooled-analysis of this potential relationship from Pubmed and EMBASE databases. For *PPARG* rs1801282 C\>G polymorphism, individuals carrying the GG and GG/CG genotype had a tendency of decreased risk to CRC risk. In colon cancer subgroup, the results of logistic regression analyses indicated that tendency was also noted. The results of subsequent meta-analysis suggested that *PPARG* rs1801282 C\>G polymorphism was associated with decreased susceptibility of CRC, especially in Asians, colon cancer and rectum cancer subgroups.

Adiposity and a sedentary lifestyle have been consistently related to CRC risk, and are vital determinants of hyperinsulinemia and insulin resistance. High concentrations of insulin or C-peptide (an insulin marker) have manifested direct association with CRC risk \[[@R33], [@R34]\]. A common functional polymorphism (Pro12Ala; rs1801282) in *PPARG* is C→G missense substitution causing a proline to alanine substitution in codon 12 of exon 2. Functional studies on *PPARG* rs1801282 polymorphism have revealed that G variant may alter the binding affinity of the protein to PPARG-responsive DNA elements compared to the C variant and the differential expression of PPARG-target genes has indicated the role of *PPARG* rs1801282 C\>G polymorphism in transcriptional activity of PPARG \[[@R13], [@R35]\]. The *PPARG* rs1801282 C→G substitution produces protein with higher activity \[[@R13], [@R36]\]. Presence of the rs1801282 C\>G polymorphism was reported to be associated with improved insulin sensitivity, lower body mass index (BMI), and a reduced risk of T2DM \[[@R37], [@R38]\]. Thus, it is possible that *PPARG* rs1801282 C\>G polymorphism may be a protective factor for colorectal cancer through insulin-related mechanisms. In our case-control study and meta-analysis, we uniformly found that *PPARG* rs1801282 G allele might decrease CRC risk. These results were consistent with the protective effect of this polymorphism, and suggest this polymorphism may confer a lower CRC risk. Several meta-analyses have been undertaken to assess the relationship between *PPARG* rs1801282 C\>G polymorphism and CRC risk \[[@R15], [@R16], [@R39]\]. In the present study, we also conducted a meta-analysis on this association including largest sample size (25 studies with 33,874 subjects). Overall, our findings of meta-analysis were consistent with those results. While in subgroup analyses, we found there were significant associations between *PPARG* rs1801282 C\>G polymorphism and decreased risk of CRC among Asians, colon cancer and rectum cancer subgroups. These results of subgroup analysis were not similar to previous meta-analyses. In our meta-analysis, more studies and more participants were recruited. Thus, our findings may be more reliable than before.

Our study has some limitations. Firstly, our case-control study was hospital-based and might be unrepresentative of the Eastern Chinese Han population. Secondly, the sample size of patients with CRC was moderate. Thirdly, some factors, such as diet, physical activity, use of non-steroidal anti-inflammatory drugs, other functional SNPs in *PPARG* gene, and etc., were not considered. In the future, well-designed studies are needed to further investigate the association thoroughly. Finally, the relationship between *PPARG* polymorphisms and CRC risk involves a complex mechanism; thus, gene-gene and gene-environment interactions should be considered in future studies.

In conclusion, our study indicates that *PPARG* rs1801282 G allele might decrease the risk of overall CRC. In the future, more case-control studies with large sample size are needed to evaluate the effect of gene-gene and gene-environment interactions of the *PPARG* rs1801282 C\>G with CRC risk.

MATERIALS AND METHODS {#s4}
=====================

Study population and patient selection {#s4_1}
--------------------------------------

Our study consisted of 387 CRC patients (236 men and 151 women) and 1,536 cancer-free controls (989 men and 547 women) in an Eastern Chinese Han population. The CRC cases were consecutively recruited from the Colorectal Surgery of Union Hospital, Fujian Medical University (Fuzhou city, China), between October 2014 and May 2016. Histologically, adenocarcinoma was confirmed via pathology. The major exclusion criteria were: patients with a history of another malignancy and hereditary nonpolyposis CRC. The controls were matched with age and gender and without any history of personal malignancy. All cancer-free controls were recruited from the Affiliated People's Hospital of Jiangsu University and the Affiliated Union Hospital of Fujian Medical University. The variables and risk factors of all participants were collected by two doctors with a pre-structured questionnaire. All participants wrote the informed consent. Data on CRC clinicopathological characteristics were extracted from the medical records. This case-control study is approved by the ethics committee of Fujian Medical University and Jiangsu University (Fuzhou city and Zhenjiang city, China). The experimental protocol was performed in strict accordance with the approved guidelines.

DNA extraction and genotyping {#s4_2}
-----------------------------

Every participant donated 2ml Ethylenediamine tetraacetic acid (EDTA)-anticoagulated intravenous blood. Genomic DNA from lymphocyte was extracted by Promega DNA Blood Mini Kit (Promega, Madison, USA). As described in previous studies, the genotyping of the rs1801282 C\>G polymorphism in *PPARG* gene was performed by a custom-by-design 48-Plex SNPscan Kit (Genesky Biotechnologies Inc., Shanghai, China) \[[@R40], [@R41]\]. This genotyping method was based on double ligation and multiplex fluorescence PCR \[[@R42]\]. For quality control, 4% of all sample sizes (seventy-seven samples) were randomly selected and were genotyped again by the same genotyping method. The results of genotyping were not changed.

Statistical analysis {#s4_3}
--------------------

Hardy-Weinberg equilibrium (HWE) was determined by an online Chi-square test (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). The association of *PPARG* rs1801282 C\>G polymorphism with CRC risk was evaluated using crude and adjusted odds ratios (ORs) with their 95 % confidence intervals (CIs) when appropriate. All statistical analyses were performed by SAS 9.4 for Windows (SAS Institute, Cary, USA). An unpaired Student's *t*-test was harnessed to check the differences for continuous variables between CRC cases and controls. And χ*2* test was used to assess the differences in the included risk factors \[e.g., smoking, drinking and body mass index (BMI)\], demographic variables, and the frequencies of various allele and genotype between CRC cases and controls. A *P* \< 0.05 (two--tailed) was defined as the level of significance.

Meta-analysis {#s4_4}
-------------

To further assess the association of *PPARG* rs1801282 C\>G polymorphism with CRC risk, we performed a comprehensive meta-analysis. Firstly, we carried out a systematic search through PubMed and EMBASE databases with the terms of 'Peroxisome proliferator activated receptor gamma' or 'PPARG' and 'polymorphism' or 'mutation' or 'variant' and 'cancer' or 'carcinoma' or 'malignancy' and 'colorectal' or 'colon' or 'rectal'. All included publications were published up to 7 October 2016. The major included criteria were: (a) case--control or cohort study based on *PPARG* rs1801282 C\>G polymorphism with sufficient genotype data and (b) the distribution of genotype in controls was in accord with HWE. The combined ORs and their 95% CIs were applied to determine the relationship of rs1801282 C\>G polymorphism in *PPARG* gene with CRC risk. The between-study heterogeneity assumption was assessed using Chi-square-based statistic *I*^2^ test and Cochran's Q-test \[[@R43]\]. When *I*^2^ \> 50% or *P* \< 0.1, we used the random-effects model (DerSimonian and Laird method) to estimate the pooled OR \[[@R44], [@R45]\]. Otherwise, the fixed effects model (the Mantel--Haenszel method) was applied \[[@R46]\]. Potential publication bias in meta-analysis was evaluated through Begg's funnel plot and the Egger's linear regression test \[[@R47]\] (*P* \< 0.1 was defined representative of statistical publication bias). The statistical analyses of meta-analysis were performed by STATA version 12.0 (Stata Corporation, College Station, TX, USA). And all *P*-values were two-sided (*P* \< 0.05). The power value of this meta-anlysis (α = 0.05) was evaluated by the Power and Sample Size Calculator (<http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize>) \[[@R48]\].
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